IL10 and inflammatory bowel disease: Studies conducted on recombinant human IL-10 (rhIL-10) for inflammatory bowel disease (IBD) have shown weak and inconsistent efficacy, partly attributable to its short half-life and the presence of pro-inflammatory properties that may counterbalance its beneficial effects [231].